)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Terns Pharmaceuticals
Terns Pharmaceuticals (TERN) investor relations material
Terns Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Key data and clinical results
TERN-701 achieved a 75% MMR rate at doses of 320 mg and above in refractory CML, with a 36% deep molecular response rate at 24 weeks.
Efficacy and safety were demonstrated in heavily pretreated, high-burden CML patients, with consistent MMR and DMR rates across baseline transcripts.
MMR achievement at all doses exceeded that of asciminib, with higher response rates and clearly separated confidence intervals.
Patient vignettes highlighted responses in individuals resistant or intolerant to multiple prior therapies, including asciminib.
87% of patients remained on treatment with a median duration of 6 months.
Safety and tolerability profile
No dose-limiting toxicities or significant adverse events were observed; maximum tolerated dose not reached.
Most treatment-emergent adverse events were low grade, with Grade 3 AEs under 10%.
No pancreatic toxicity or significant blood pressure changes reported.
Once-daily dosing is possible without food restrictions, enhancing convenience.
Market and competitive landscape
TERN-701 targets a $5B+ CML market and is positioned as a next-generation allosteric inhibitor with potential to capture majority market share due to superior efficacy, safety, and convenience.
Asciminib, the first allosteric inhibitor, achieved 22% front-line market share within three quarters and is projected to exceed $4 billion in sales.
Despite asciminib's success, unmet needs remain due to efficacy and safety limitations, especially in high-burden or previously treated patients.
Allosteric inhibitors like TERN-701 and asciminib are rapidly adopted across CML treatment lines.
Historical trends in CML therapy adoption suggest rapid uptake for therapies with improved profiles.
Rationale for adding asciminib to frontline control arm
Why is TERN-701 limited to CML indications?
Key 2026 milestones for TERN-701 development
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Terns Pharmaceuticals earnings date
Q4 202523 Mar, 2026
Terns Pharmaceuticals
Next Terns Pharmaceuticals earnings date
Q4 202523 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the development of a diverse portfolio of small-molecule therapeutic candidates. The company's research and development efforts are primarily focused on addressing serious diseases, including oncology, non-alcoholic steatohepatitis (NASH), and obesity.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage